MASTERINVEST Kapitalanlage GmbH Makes New Investment in Insmed, Inc. $INSM

MASTERINVEST Kapitalanlage GmbH acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,640 shares of the biopharmaceutical company’s stock, valued at approximately $759,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Insmed during the fourth quarter valued at approximately $506,625,000. RTW Investments LP grew its position in Insmed by 57.0% during the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after purchasing an additional 1,758,321 shares in the last quarter. Orbis Allan Gray Ltd purchased a new position in Insmed during the 2nd quarter worth approximately $153,389,000. State Street Corp lifted its holdings in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after purchasing an additional 1,217,390 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after buying an additional 1,140,524 shares during the period.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $109.81 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The business’s 50-day moving average price is $105.54 and its two-hundred day moving average price is $136.60. The company has a market capitalization of $23.80 billion, a P/E ratio of -19.10 and a beta of 0.78.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period last year, the business earned ($1.42) EPS. Analysts anticipate that Insmed, Inc. will post -2.52 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 21,398 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. This represents a 7.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 54,590 shares of company stock worth $5,793,738. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. Leerink Partners upped their price target on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research report on Tuesday, March 24th. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Bank of America upped their target price on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.05.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.